Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
In-depth stories
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
Poster selection
Blood-derived cell-free DNA for disease monitoring in patients with multiple myeloma
December 20, 2024
In his poster presented at ASH 2024, Dr Robbe Heestermans, clinical biologist in training at the University Hospital Brussels (Brussel, Belgium), shares the results of his research into peripheral blood-based
Tagraxofusp induces a rapid restoration of normal hematopoiesis in patients with newly-diagnosed BPDCN
December 20, 2024
During ASH 2024, Prof Dr Marina Konopleva from the Albert Einstein College of Medicine (Bronx, NY, USA) presented the results of a sub analysis of a phase II study evaluating
Impact of emicizumab on mental liberation in haemophilia A patients
December 20, 2024
Prof Dr Cédric Hermans, a haematologist at Cliniques Universitaires Saint-Luc in Brussels presented data on emicizumab, a new treatment for haemophilia A.
Momelotinib for myelofibrosis with anaemia: Spanish real-world data
December 12, 2024
Dr Lucia Pérez-Lamas, a haematologist at Hospital Universitario Puerta de Hierro, Madrid, Spain, presented real-world data on momelotinib for myelofibrosis patients with anaemia, collected from 54 patients across 74 centres.
Return to work after allogeneic stem cell transplantation (SOPRALLO project)
July 17, 2024
Dr Yana Stepanishyna, a haematologist at the Institut Jules Bordet in Brussels, presents a preliminary analysis from the SOPRALLO project.
Allogeneic hematopoietic stem cell transplantation (HSCT) has significantly extended
Matching-adjusted indirect comparisons of bispecific antibodies in R/R FL
July 17, 2024
Epcoritamab (EPCOR) is a novel, subcutaneous CD3xCD20 bispecific antibody (bsAb) that has demonstrated deep and durable responses with manageable safety in patients with R/R FL following at least two systemic
Targeting the IL-4 pathway in T-ALL patients
July 17, 2024
Wouter Sleeckx, a doctoral researcher at the University of Ghent, presented his research on the therapeutic potential of targeting the IL-4 signalling pathway in a subset of T-ALL patients. His
Functional characterisation of kdm6b in immature leukemia
July 17, 2024
Cristina Borin, a doctoral researcher at the University of Ghent and the Cancer Research Institute Ghent (CRIG) presented her work on the functional characterization of Kdm6b in immature leukemia. Her